Ad
Appetite-suppressing drugs have generated popular excitement, and endless coverage in mainstream media, but potential side effects and addiction issues mean the drug revolution is not happening without concerns. (Photo: CGP Grey)

Concerns remain over successful 'cure' for obesity

Two months after Danish pharmaceutical company Novo Nordisk launched Wegovy — its blockbuster weight-loss drug — in Europe, demand has exploded.

Overweight Germans are desperate to get a hold of the drug, hoping to lose weight. 48-year-old Philipp Lang from Bad Homburg, near Frankfurt in Germany is one of them.

Lang has a background in investment banking and IT. He runs a family business, acting as the managing director of an illumination company in Friedrichsdorf while running r...

To read this story, log in or subscribe

Enjoy access to all articles and 25 years of archives, comment and gift articles. Become a member for as low as €1,75 per week.

Already a member? Login

Author Bio

Mie Hoejris Dahl is a Danish freelance journalist based in Mexico City, Mexico.

Appetite-suppressing drugs have generated popular excitement, and endless coverage in mainstream media, but potential side effects and addiction issues mean the drug revolution is not happening without concerns. (Photo: CGP Grey)

Tags

Author Bio

Mie Hoejris Dahl is a Danish freelance journalist based in Mexico City, Mexico.

Ad

Related articles

Ad
Ad

Latest News